A comparative study of the in vitro antitumor effect of mannose‐doxorubicin conjugates with different linkers

Cui, Xinxin; Du, Kunda; Yuan, Xiaoyin; Xiao, Wen; Tao, Yayu; Xu, Defeng; Hu, Hang

doi:10.1002/ddr.21896

Cited by 6 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hydrodynamic diameters of IR820-ss-PEG and Cur@IR820-ss-PEG are 150.0 ± 3.7 nm and 125.3 ± 4.5 nm, respectively, and both of them have negative zeta potentials, Table S2 . To better understand the self-assembly behaviors and structures of Cur@IR820-ss-PEG, DPD simulation was performed [ 44 ]. DPD is a coarse-grained simulation method suitable for mesoscale simulation.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Reduction-responsive worm-like nanoparticles for synergistic cancer chemo-photodynamic therapy

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“…The in vitro singlet oxygen generation of IR820-ss-PEG was studied using DPBF as a singlet oxygen trapping agent [ 44 , 47 , 48 ]. As shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Reduction-responsive worm-like nanoparticles for synergistic cancer chemo-photodynamic therapy

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

“…2.4 | Synthesis of DTX-(DSeDPA-Gal) 2 3,3′-Diselenodipropionic acid was synthesized according our previously reported method (Cui et al, 2021). Briefly, selenium (1.6 g) and NaBH 4 (1.5 g) were dispersed in 20 mL of deionized water and dissolved in 10 mL of deionized water, respectively.…”

Section: Synthesis Of Dtx-(dtdpa-gal)mentioning

confidence: 99%

Synthesis and in vitro antitumor activity of galactosamine–docetaxel conjugates

Shen,

Cheng,

et al. 2024

Chem Biol Drug Des

Self Cite

View full text Add to dashboard Cite

Docetaxel (DTX) is a semi‐synthetic analogue of paclitaxel which has attracted extensive attention in the treatment of cancer. However, the current clinically used DTX formulations display low tumor targeting ability, leading to unsatisfactory therapeutic outcomes with adverse effects, which poses significant challenges to the clinical application. In this study, three galactosamine (Gal) and docetaxel conjugates with different linkers were synthesized, namely DTX‐(suc‐Gal)2, DTX‐(DTDPA‐Gal)2, and DTX‐(DSeDPA‐Gal)2. These three conjugates were characterized by 1H NMR, FT‐IR and HRMS. The in vitro drug release study shows that DTX‐(DTDPA‐Gal)2 and DTX‐(DSeDPA‐Gal)2 exhibit glutathione (GSH)‐responsive drug release and DTX‐(DSeDPA‐Gal)2 displays higher GSH‐responsiveness. The in vitro antitumor activity study shows that DTX‐(DTDPA‐Gal)2 and DTX‐(DSeDPA‐Gal)2 exhibit enhanced cytotoxicity, cell apoptosis rate and G2/M phase arrest against HepG2 cells as compared to DTX‐(suc‐Gal)2, DTX‐(DSeDPA‐Gal)2 displays the highest cytotoxicity, cell apoptosis rate and G2/M phase arrest among these three conjugates. In addition, DTX‐(DSeDPA‐Gal)2 exhibits higher selectivity to HepG2 cells as compared to free DTX. The DTX‐(DSeDPA‐Gal)2 developed in this study has been proven to be an effective DTX conjugate for selective killing hepatoma cells.

show abstract

“…Compared with nanocarriers which often have sophisticated fabrication process, carrier‐related potential biocompatibility issues and low drug loading content, ligand‐drug conjugates are carrier free and have the advantages of high drug loading content and targeting tumor cells by ligand‐receptor interactions. To now, various ligand‐drug conjugates have been developed for tumor‐targeted anticancer drug delivery (Cui et al., 2022; Hu, Wang, et al., 2019; Liang et al., 2018; Yuan et al., 2022).…”

Section: Introductionmentioning

confidence: 99%

Biotin‐new indocyanine green conjugate: Synthesis, in vitro photocytotoxicity and in vivo biodistribution

Liu,

Ding,

et al. 2024

Chem Biol Drug Des

Self Cite

View full text Add to dashboard Cite

New indocyanine green (ICG) (IR820) is one of the ICG derivatives and attracts increasing attention for cancer management. However, the unsatisfactory tumor targeting ability of IR820 significantly limits its applications for cancer theranostics. Biotin receptor is overexpressed on the membrane of various tumor cells and biotin modified nanocarriers have been reported to enhance the tumor targeting ability on several tumor types. In this work, biotin‐new ICG conjugate (Biotin‐SS‐IR820) was prepared for tumor‐targeted IR820 delivery. Biotin and IR820 were coupled through cystamine. The synthesized Biotin‐SS‐IR820 was characterized by 1H NMR, FT‐IR and HRMS. The in vitro singlet oxygen generation study shows that Biotin‐SS‐IR820 exhibits similar singlet oxygen generation as compared to IR820 upon 660 nm laser irradiation (0.8 W/cm2). The cellular uptake study shows that Biotin‐SS‐IR820 shows enhanced cellular uptake amount as compared to IR820 on 4T1 cells. As a result, Biotin‐SS‐IR820 displays enhanced in vitro photodynamic therapeutic effect against 4T1 cells as compared to IR820. In in vivo biodistribution study, Biotin‐SS‐IR820 shows enhanced tumor accumulation as compared to IR820. Biotin‐SS‐IR820 developed in this work shows promising prospects for targeted delivery of IR820 to biotin receptor overexpressed tumors.

show abstract

A comparative study of the in vitro antitumor effect of mannose‐doxorubicin conjugates with different linkers

Cited by 6 publications

References 42 publications

Reduction-responsive worm-like nanoparticles for synergistic cancer chemo-photodynamic therapy

Reduction-responsive worm-like nanoparticles for synergistic cancer chemo-photodynamic therapy

Synthesis and in vitro antitumor activity of galactosamine–docetaxel conjugates

Biotin‐new indocyanine green conjugate: Synthesis, in vitro photocytotoxicity and in vivo biodistribution

Contact Info

Product

Resources

About